Annexon, a clinical-stage biopharmaceutical company that focuses on drugs for autoimmune and neurodegenerative disorders has raised $100 million in Series C financing.
The funding will be used to accelerate their clinical and preclinical programs to combat classical complement-mediated diseases. The multiple product candidates in Annexon’s portfolio include:
Annexon funding was led by new investor Redmile Group. Additional new investors included BlackRock, Deerfield Management Company, Eventide Asset Management, Farallon Capital Management, Janus Henderson Investors and Logos Capital, in addition to existing investors.